Back to Search Start Over

Extracellular domain of semaphorin 5A serves a tumor‑suppressing role by activating interferon signaling pathways in lung adenocarcinoma cells.

Authors :
Chen MZ
Su LY
Ko PH
Hsu MH
Chuang LL
Chen LH
Lu TP
Chuang EY
Chow LP
Tsai MH
Hsu HH
Lai LC
Source :
International journal of oncology [Int J Oncol] 2022 Feb; Vol. 60 (2). Date of Electronic Publication: 2022 Jan 21.
Publication Year :
2022

Abstract

Semaphorin 5A (SEMA5A), which was originally identified as an axon guidance molecule in the nervous system, has been subsequently identified as a prognostic biomarker for lung cancer in nonsmoking women. SEMA5A acts as a tumor suppressor by inhibiting the proliferation and migration of lung cancer cells. However, the regulatory mechanism of SEMA5A is not clear. Therefore, the purpose of the present study was to explore the roles of different domains of SEMA5A in its tumor‑suppressive effects in lung adenocarcinoma cell lines. First, it was revealed that overexpression of full length SEMA5A or its extracellular domain significantly inhibited the proliferation and migration of both A549 and H1299 cells using MTT, colony formation and gap closure assays. Next, microarray analyses were performed to identify genes regulated by different domains of SEMA5A. Among the differentially expressed genes, the most significant function of these genes that were enriched was the 'Interferon Signaling' pathway according to Ingenuity Pathway Analysis. The activation of the 'Interferon Signaling' pathway was validated by reverse transcription‑quantitative PCR and western blotting. In summary, the present study demonstrated that the extracellular domain of SEMA5A could upregulate genes in interferon signaling pathways, resulting in suppressive effects in lung adenocarcinoma cells.

Details

Language :
English
ISSN :
1791-2423
Volume :
60
Issue :
2
Database :
MEDLINE
Journal :
International journal of oncology
Publication Type :
Academic Journal
Accession number :
35059729
Full Text :
https://doi.org/10.3892/ijo.2022.5311